With more than twenty-five years’ experience in the biopharmaceutical industry, Eduardo Bravo has a strong track record in leading international biotech and pharmaceutical organizations. He joined LSP as Partner in 2021. He is currently CEO of EBAC (European Biotech Acquisition Corporation), a Nasdaq’s listed SPAC sponsored by LSP with focus on European biotech companies. Prior to this role he was CEO of Nordic Nanovector, a biotech company developing targeted therapies for haematological cancers. As CEO of TiGenix, he successfully developed the company through several financing rounds, led its IPO on NASDAQ, and secured EMA approval of its lead asset. Prior to joining TiGenix’s predecessor, Cellerix, in 2005, he held several senior management positions at Sanofi-Aventis and SmithKline Beecham. Mr. Bravo holds a degree in Business Administration and an MBA (INSEAD). He is President of the EBE (European Biopharmaceutical Enterprises) Board of Directors and member of the Executive Committee of ARM (Alliance for Regenerative Medicine).